LRP1B and colorectal carcinoma: Additionally, LRP1B, KMT2B and TSC2 mutations appear to be novel findings in the context of early‐stage lymph node metastasis in CRC, indicating that they could potentially be unique markers for predicting outcomes in T1/2 patients (Figure 3).